Patients with nonlocalized bronchiectasis are frequently encountered; yet, little is known about surgical management in this patient group. This study was determined to assess the clinical response and safety of anatomic excision of the primary lesion via lobectomy for nonlocalized bronchiectasis therapy. Between 2010 and 2013, researchers looked at the medical records of 37 patients who had lobectomy via thoracotomy for nonlocalized bronchiectasis. Nonlocalized bronchiectasis with one prominent lesion, failure of medicinal treatment, and adequate cardiopulmonary reserve was the main surgical indications. Preoperative computed tomography and bronchoscopy were used to determine the primary lesion. They assessed preoperative symptoms were compared to postoperative symptoms using paired approaches,
The average age of the patients was 54.5 ± 6.4 years. There were no surgical deaths. About Eight (21.6%) of the patients had postoperative complications, including one with empyema, one with persistent air leak, and six with minor transient issues, all of which were controllable without the need for reoperation. After lobectomy, the median extent of residual bronchiectatic regions in the remaining lungs was 25%. (range, 12.5% -42.9%). Acute infection (5.3 ± 2.1/year vs. 1.8 ± 2.3/year) and hemoptysis (4.9 ± 2.8/year vs. 1.1 ± 0.7/year) were both significantly reduced, as was the volume of sputum (37.1 ± 3.4 mL/day vs. 10.7 ± 4.6 mL/day). After surgery, 23 (62.2%) patients were asymptomatic, 10 (27.0%) were symptomatic with clinical improvement, and 4 (10.8%) had no change or increased symptoms. In the surgical treatment of nonlocalized bronchiectasis, lobectomy for the primary lesion is a safe operation that provides great symptom alleviation and high patient satisfaction.